Drug Trial Radar · NCT03925233
Breast Cancer Treatment Based on Organ-like Culture
Last checked: Nov 20, 2026Latest source record: Apr 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
300
Planned (sponsor's estimate)
Start
Jan 2, 2019
Primary completion
Dec 15, 2021
Study completion Dec 15, 2021
Sponsor
- Lead sponsor
- Xijing HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 24, 2019
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.
Conditions
- Breast Cancer Organoids
Interventions
TrastuzumabDrug
Trastuzumab Injection
Doxorubicin HydrochlorideDrug
Doxorubicin Hydrochloride Injection
Epirubicin hydrochlorideDrug
Epirubicin hydrochloride injection
FluorouracilDrug
Fluorouracil injection
PaclitaxelDrug
Paclitaxel injection
GemcitabineDrug
Gemcitabine injection
CisplatinDrug
Cisplatin injection
Recombinant Human EndostatinDrug
Recombinant Human Endostatin Injection
Pirarubicin hydrochlorideDrug
Pirarubicin hydrochloride injection
PyrrolidineDrug
Pyrrolidine tablets
IxabepiloneDrug
Ixapilone Injection
Tamoxifen citrateDrug
Tamoxifen citrate tablets
Vinorelbine tartrateDrug
Vinorelbine tartrate injection
CarboplatinDrug
Carboplatin injection
MethotrexateDrug
Methotrexate injection
Eribulin mesylateDrug
Eribulin mesylate injection
Toremifene citrateDrug
Toremifene citrate tablets
AnastrozoleDrug
Anastrozole tablets
LetrozoleDrug
Letrozole tablets
ExemestaneDrug
Exemestane tablets
FulvestrantDrug
Fulvestrant injection
OlaparibDrug
Olapani pill
BevacizumabDrug
Bevacizumab injection
Apatinib mesylateDrug
Apatinib mesylate tablets
PattozumabDrug
Pattozumab injection
CapecitabineDrug
Capecitabine tablets
Ear particlesDrug
Ear particles
Aidi InjectionDrug
Aidi Injection
CyclophosphamideDrug
Cyclophosphamide injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Detection of cell viabilityTime frame: 8 weeks before neoadjuvant chemotherapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
JingSu
Xi'an, Shaanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.